← Back to Analyst Consensus 
NRIX Buy
Nurix Therapeutics, Inc.
Current Price —
Implied Upside —
Analysts 20
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 6 reiterations from 6 firms
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 16, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Oct 13, 2026 | RBC Capital | maintain | Outperform → Outperform | — | 55% |
| Oct 13, 2026 | Oppenheimer | maintain | Outperform → Outperform | — | 52% |
| Oct 13, 2026 | Truist Securities | maintain | Buy → Buy | — | 54% |
| Oct 13, 2026 | Baird | maintain | Outperform → Outperform | — | 55% |
| Oct 13, 2026 | Needham | reiterate | Buy → Buy | — | 50% |
| Aug 10, 2026 | RBC Capital | maintain | Outperform → Outperform | — | 55% |
| Aug 4, 2026 | Needham | reiterate | Buy → Buy | — | 50% |
| Jul 28, 2026 | Morgan Stanley | maintain | Overweight → Overweight | — | 54% |
| Jul 22, 2026 | UBS | maintain | Buy → Buy | — | 54% |
| Jul 13, 2026 | Mizuho | maintain | Outperform → Outperform | — | 52% |
| Jul 10, 2026 | Truist Securities | maintain | Buy → Buy | — | 54% |
| Jul 10, 2026 | RBC Capital | maintain | Outperform → Outperform | — | 55% |
| Jul 10, 2026 | Stifel | maintain | Buy → Buy | — | 53% |
| Jul 10, 2026 | BTIG | reiterate | Buy → Buy | — | 52% |
| Jul 10, 2026 | Needham | reiterate | Buy → Buy | — | 50% |
| Jul 10, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Jun 18, 2026 | Baird | maintain | Outperform → Outperform | — | 55% |
| Jun 15, 2026 | Needham | reiterate | Buy → Buy | — | 50% |
| Jun 10, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Jun 9, 2026 | Truist Securities | maintain | Buy → Buy | — | 54% |
| Jun 9, 2026 | BTIG | maintain | Buy → Buy | — | 52% |
| Jun 8, 2026 | Jefferies | maintain | Buy → Buy | — | 52% |
| Jun 8, 2026 | Wells Fargo | maintain | Overweight → Overweight | — | 54% |
| Jun 8, 2026 | Needham | maintain | Buy → Buy | — | 50% |
| May 18, 2026 | BTIG | reiterate | Buy → Buy | — | 52% |
| Apr 27, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Apr 23, 2026 | Needham | reiterate | Buy → Buy | — | 50% |
| Apr 10, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Apr 9, 2026 | Wells Fargo | maintain | Overweight → Overweight | — | 54% |
| Apr 8, 2026 | Needham | reiterate | Buy → Buy | — | 50% |
| Mar 24, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Jan 29, 2026 | Piper Sandler | maintain | Overweight → Overweight | $35 | 54% |
| Jan 29, 2026 | RBC Capital | maintain | Outperform → Outperform | $30 | 55% |
| Jan 29, 2026 | Stifel | maintain | Buy → Buy | $35 | 53% |
| Jan 29, 2026 | Wells Fargo | maintain | Overweight → Overweight | $29 | 54% |
| Jan 29, 2026 | BTIG | reiterate | Buy → Buy | $30 | 52% |
| Jan 29, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | $32 | 44% |
| Jan 29, 2026 | Needham | reiterate | Buy → Buy | $26 | 50% |
| Jan 8, 2026 | Morgan Stanley | upgrade | Equal-Weight → Overweight | $36 | 54% |
| Dec 16, 2025 | Wells Fargo | maintain | Overweight → Overweight | $30 | 54% |
| Dec 10, 2025 | Mizuho | maintain | Outperform → Outperform | $30 | 52% |
| Dec 10, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $31 | 44% |
| Dec 9, 2025 | BTIG | maintain | Buy → Buy | $30 | 52% |
| Dec 8, 2025 | Needham | reiterate | Buy → Buy | $26 | 50% |
| Nov 4, 2025 | Needham | reiterate | Buy → Buy | $26 | 50% |
| Nov 4, 2025 | BTIG | reiterate | Buy → Buy | $27 | 52% |
| Oct 27, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $28 | 44% |
| Oct 23, 2025 | Wells Fargo | maintain | Overweight → Overweight | $21 | 54% |
| Oct 23, 2025 | BTIG | maintain | Buy → Buy | $27 | 52% |
Price Target Trend
Jun 13, 2026 Latest: $34.5 Oct 25, 2026
EPS Estimates
0q $1.51
Lo: $-0.64 Hi: $5.26
3 analysts +1y $-1.28
Lo: $-2.48 Hi: $-0.62
3 analysts +1q $-0.59
Lo: $-0.59 Hi: $-0.59
1 analysts ▲3
0y $3.02
Lo: $2.96 Hi: $3.10
3 analysts Cross-Platform Signals
No cross-platform signals in the last 90 days